Innovent Updates Phase 1b Data of IBI939 (Anti-TIGIT Monoclonal Antibody) Combined with Sintilimab in Previously Untreated PD-L1-selected NSCLC at the 2023 ASCO Annual Meeting ...Middle East

ROCKVILLE, Md. and SUZHOU, China, June 3, 2023 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, metabolic,...

Hence then, the article about innovent updates phase 1b data of ibi939 anti tigit monoclonal antibody combined with sintilimab in previously untreated pd l1 selected nsclc at the 2023 asco annual meeting was published today ( Sunday 04/06/2023 - 03:16 AM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Innovent Updates Phase 1b Data of IBI939 (Anti-TIGIT Monoclonal Antibody) Combined with Sintilimab in Previously Untreated PD-L1-selected NSCLC at the 2023 ASCO Annual Meeting )

Also on site :

• '70s Rock Legend, 76, Releases 'Beautiful' New Single Fans Are Calling a 'Magnificent Piece of Music'
• Ben Affleck & Jeopardy! Star Jamie Ding Take Home $1 Million on 'Millionaire' After a Surprise Assist on the Final Answer
• SOB vs BPH Dream11 Prediction Today Match, Dream11 Team Today, Fantasy Cricket Tips, Playing XI, Pitch Report, Injury Update- English Men’s 100 League 2026, Match 13